harmful, or ineffective. Limitations include underestimation of interim publications (full text not searched), the final publication rate (missed publications or misclassified trials eligible for publication), and the extent of interim to final changes (only 1 key outcome analyzed).
1.
Stephens RJ, Langley RE, Mulvenna P, Nankivell M, Vail A, Parmar MK. Interim results in clinical trials: do we need to keep all interim randomised clinical trial results confidential ? Lung Cancer. 2014; 85(2) :116-118.
2.
Wang H, Rosner GL, Goodman SN. Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research. Clin Trials. 2016; 13(6) :621-631. 
Trialists' Intent to Share Individual Participant Data as Disclosed at ClinicalTrials.gov
The US Institute of Medicine and the International Committee of Medical Journal Editors (ICMJE), among others, have called for clinical trialists to declare their plans to share individual participant data (IPD) and related study documents for secondar y research prior to study initiation.
1-3 Individual participant data, which refers to measurements collected from each research participant, is distinct from aggregated data usually reported in journal articles or in the ClinicalTrials.gov results database.
1
The term IPD sharing refers to the practice of making clinical trial data at the individual level available to researchers who were not part of the original study team.
4
In December 2015, ClinicalTrials.gov added 2 optional registration fields for disclosing trialists' intentions about IPD sharing: (1) plan to share IPD? and (2) available IPD/information type (Box). In this exploratory study, we characterized responses to both fields to inform the ongoing discussion.
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Box. Description of the 2 ClinicalTrials.gov Individual Participant Data (IPD) Sharing-Related Optional Registration Fields
Plan to Share IPD (generally provided at study initiation)
Indicate whether there is a plan to make IPD collected in this study, including data dictionaries, available to other researchers (typically after the end of the study). Options include: Yes: There is a plan to make IPD and related data dictionaries available; No: There is not a plan to make IPD available; Undecided: It is not yet known if there will be a plan to make IPD available.
IPD Sharing Plan Description
If response to the plan to share IPD field is "yes," briefly describe what specific individual participant data sets are to be shared (for example, all collected IPD, all IPD that underlie results in a publication). If response to the plan to share IPD field is "no" or "undecided," an explanation may be provided for why IPD will not be shared or why it is not yet decided.
Available IPD/Information Type (generally provided after study completion)
The type of data set or supporting information being shared. Options include: individual participant data set, study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code, or other (specify) Methods | We summarized and examined responses from both ClinicalTrials.gov IPD-related fields for all interventional studies registered from January 2016 to August 2017. We also extracted a nonrandom convenience sample of unique freetext plan descriptions from records indicating plans to share IPD for a qualitative review and to determine if any misunderstanding of the definition of IPD sharing was present.
For trial records from high-volume registrants (registered ≥10 records), we characterized disclosed plans to share IPD. We further characterized responses from the top-10 highvolume registrants within each key funder type. Key funder types were categorized as "NIH" if at least 1 National Institutes of Health (NIH) institute or center was listed as the lead sponsor or collaborator, as "industry" if not classified as NIH and at least 1 company was listed as the lead sponsor or collaborator, and as "other" for all remaining records (eg, funded by foundations).
Results | Of 35 621 trial records analyzed on August 31, 2017, 25 551 (72%) responded to the Plan to Share IPD field; 2782 records (10.9%) indicated yes, 6452 (25.3%) indicated undecided, and 16 317 (63.9%) indicated no. Of records indicating plans to share IPD, we reviewed 154 free-text descriptions of sharing plans and identified at least 5 types of misunderstanding of IPD sharing (eg, suggesting that sharing would be done through publication or posting on trial registers, that data would be provided to the participants, or that data would be shared with a limited number of groups, etc).
Of the 35 621 records analyzed, 20 842 (58.5%) were from 693 high-volume registrants; 14 040 (67%) included a response to the plan to share IPD field, with 5% indicating yes, 16% undecided, and 50% no (Table) . Proportions varied by key funder type, from 11% of NIH funders to 0% of industry answering yes. Among the top-10 high-volume registrants by key funder type, the median for percentage of records indicating existence of IPD sharing plans was 7% (range, 0%-18%) for NIHfunded studies, 0% (range, 0%-27%) for industry-funded studies, and 5% (range, 0%-14%) for studies with other funding.
Among 212 trial records (of 35 621) listing entries in the available IPD/information type field, 19 specified that IPD would be available for sharing. Of these 19 records, 7 had responded no to the plan to share IPD registration field, 6 had indicated that IPD sharing was planned, 5 had indicated undecided, and 1 had not responded. Based on this early experience, ClinicalTrials.gov added additional subfields with greater structure in late June 2017 to facilitate more complete disclosure of IPD-sharing plans as required by the ICMJE.
2,6 However, considerable educational, cultural, and scientific changes will be necessary before the sharing of IPD and associated documents is well understood. 
Prevalence of Disclosed Conflicts of Interest in Biomedical Research and Associations With Journal Impact Factors and Altmetric Scores
Conflict of interest disclosures are an indicator of risk of bias in biomedical research 1 and are associated with reporting of statistically significant results in primary studies. 2 Although prevalence data are lacking, some suggest conflict of interest is widespread, unavoidable, and even desirable.
3,4
Our aim was to estimate the prevalence of conflict of interest disclosure, extending beyond previous studies of specific populations, settings, or outcomes 5, 6 and to determine whether the presence of a published conflict of interest disclosure was associated with attention in the scientific literature and media.
Methods | We conducted a cross-sectional study of all articles published between January 1, 2016, and December 31, 2016, in journals conforming to the International Committee of Medical Journal Editors (ICMJE) policies and indexed in PubMed. Articles were randomly sampled to reach a prespecified sample size of 1000. We included primary research articles, commentaries, editorials, narrative reviews, systematic reviews, and meta-analyses without language restrictions. Disclosures were classified as positive when at least 1 author reported a conflict of interest of any type, excluding current study funding or industry employment; negative if all authors stated they had no conflicts; and missing if there was no disclosure statement. Article focus was classified as drugs, devices or surgery, or neither. Journal impact factors were taken from the Journal Citation Reports 2016. Altmetric score was used to estimate media attention (mainstream media, social media, blogs, and other sources). All articles with a positive disclosure were examined by 2 investigators (Q.G. and A.G.D.) .
The primary outcome was prevalence of positive disclosures with 95% CIs calculated using the Clopper-Pearson exact method. We used χ 2 tests for differences in the prevalence of disclosed conflicts of interest by article type and focus, and Kruskal-Wallis tests for differences in the median journal impact factors and Altmetric scores across categories of articles. The threshold for significance was a 2-sided P value less than .05, adjusting for multiple comparisons using a Bonferroni correction. Analyses were conducted using SPSS version 24 (IBM) and Matlab version R2016a (MathWorks). Table 2 ). Patterns were similar by article type and focus. Although striking, the results for systematic reviews and meta-analyses were not significant, likely due to the small sample size (n = 30).
Results
Discussion | Among articles expected to conform to ICMJE disclosure standards, 22.9% included a positive conflict of interest disclosure. This cross-sectional analysis of articles published in 2016 did not associate disclosures with bias, nor did it account for undisclosed conflicts of interest. These estimates confirm that disclosures are more concentrated in certain types of studies. The highest prevalence of a positive disclosure was among articles most likely to contain subjective opinions. Articles with a positive disclosure were published in journals with higher impact factors and received more media attention and, thus, are likely to receive more attention from both the research community and the public. This may distort the perception of how common conflicts of interest are and amplify the effect of their results.
To enhance transparency, journals should enforce requirements that manuscripts include both disclosures and funding statements. Adoption of a standardized nomenclature for the types of conflicts of interest would enable the sharing of author conflicts in a public registry and may provide a clearer analysis of their potential influence on research integrity.
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